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This report reviews information on Serious Adverse Events
(SAE), mainly Loa-encephalopathy, following treatment
with ivermectin (Mectizan®, Merck, Sharpe & Dohme) for
control of onchocerciasis carried out by the African Pro-
gramme for Onchocerciasis Control (APOC), in areas
where heavy microfilarial infections with Loa loa are co-
endemic with Onchocerca volvulus infections. It also
endeavours to define the information and research
needed to understand, prevent, and manage cases of Loa-
encephalopathy.
In coping with the recent appearance of the risk of Loa-
encephalopathy, the Mectizan® Expert Committee and its
secretariat, the Mectizan® Donation Program (MDP), and
the national onchocerciasis control programmes, involv-
ing APOC and associated Non-Governmental Develop-
ment Organizations (NGDOs), have to assess the benefits
of mass treatment in preventing the blindness and
unpleasant skin manifestations of onchocerciasis in large
numbers of infected persons, against the risk of inciting
severe and sometimes fatal reactions of Loa-encephalopa-
thy in a small proportion of treated persons living in areas
of high Loa  co-endemicity. In practical terms, this
dilemma raises a number of problems and implies the
need for much extra effort and costs in the field prior to,
during, and shortly after community distribution of Mec-
tizan®.
As Haselow et al., [1] point out, the risk of Loa-encepha-
lopathy demands better explanation of the benefit/risk
ratio in those communities to be treated by APOC
wherein L. loa and O. volvulus are co-endemic, and also
more careful control of stocks of Mectizan®. It demands a
reinforced health-education campaign in favour of taking
Mectizan®. It will mean confining Mectizan® treatment
more rigidly to hyper- and meso-endemic onchocerciasis
communities, which in turn implies more accurate Rapid
Epidemiological Assessment (REA) to exclude hypo-
endemic onchocerciasis communities. Where treatment is
to go ahead, the population must be made aware, without
inciting undue alarm, of the early signs of Loa-encepha-
lopathy so as to facilitate rapid referral of such cases to
hospital; and each potential referral hospital needs to
have a team of at least four persons who are trained to deal
with Loa-encephalopathy cases. In terms of practical field
assessment, the models explored by Addiss et al., [2] sug-
gest that accurate REA identification of hyper- and meso-
endemic onchocerciasis communities, coupled with a
RAPLOA limit of 20% of persons with a history of Loa
worms crossing the eyeball, is probably the currently best
safety limit to apply.
Collections of data from past reports submitted to the
MDP have been carefully analysed by Twum-Danso [3,4]
who indicates that, among all 207 SAEs recorded by pas-
sive surveillance during 165,000,000 Mectizan®  treat-
ments (1:800,000) carried out between 1989 and 2001,
there were 65 (31·4%) cases of "probable" or "possible"
Loa-encephalopathy temporally related to Mectizan®
treatment. Of them:
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i) 85 % were in males;
ii) 93% followed the first dose of ivermectin;
iii) 97% were from Cameroon;
iv) The mean age of the subjects was 39·9 years (Range 6
– 89)
v) Mean time to onset of symptoms was 1·7 days;
vi) Mean time to first medical attention was 2·0 days;
vii) Mean period of hospitalization (53 cases) was 27·5
days
Outcome: (34 cases):
i) 23·5% were fatal;
ii) 11·8% had partial residual neurological deficit;
iii) and 64·7% recovered fully
Mean concentrations of microfilariae (mfs) Loa  in the
peripheral blood (32 cases) were:
i) Pre-treatment – 164,250 mfs/ml
ii) Post-treatment (< 1 month) – 3,926 mfs/ml
iii) Post-treatment (< 5–6 months) – 7,800 mfs/ml
The clinical manifestations of Loa-encephalopathy are
well described by Boussinesq et al. [5]. Hospital staff in
areas at risk of Loa-encephalopathy need to be familiar
especially with:
i) the neurological symptoms and signs, and haemor-
rhages of the palpebral conjunctiva (HPCs) and their time
of onset;
ii) the vital importance of good-nursing of cases to pre-
vent bed-sores and of re-hydration;
iii) the likely duration of the various stages of the disease;
and
iv) the probable diagnostic concentrations of Loa mfs to
be found in such cases at various intervals post-treatment.
All the above considerations will inevitably add consider-
able costs and effort to the activities of the MDP and
APOC in the co-endemic Loa areas concerned.
To date, cases of sometimes fatal ivermectin-induced Loa-
encephalopathy show a very remarkable distributional
clumping in one particular Health Area (Lékié) in the
Republic of Cameroon; but it should be remembered that
similar Loa-encephalopathies have been reported follow-
ing treatment of individual loiasis sufferers with diethyl-
carbamazine citrate (DEC), which is both a potent
microfilaricide and a fairly effective macrofilaricide for L.
loa. Again there was evidence of distributional clumping,
this time in the Mayumbe Region of the Democratic
Republic of the Congo (DRC), where 80–90 cases were
recorded over 10 years in a single hospital [6]. This
appears to be another potentially dangerous area that is
only now about to be covered by the activities of APOC,
and one that may well give rise to difficulties. This remark-
able clumping of cases may eventually provide a clue to
the causation of Loa-encephalopathy. On the other hand,
more mundane aspects involving the different Health
Areas, particularly in Cameroon, need also to be taken
into account. The authorities in Health Areas that provide
free hospital treatment for sufferers (e.g. Lékié) are likely
to be made aware of many more cases of Loa-encephalop-
athy than those in which patients are expected to pay for
their treatment and may thus prefer to remain hidden in
their homes.
The Report emphasizes the importance of an experimen-
tal approach to determine
(i) the factors governing the remarkably uneven distribu-
tion of cases within the Loa-endemic area;
(ii) the practical means of detecting communities that are
at high risk of Loa-encephalopathy;
(iii) the clinical symptoms and signs that characterise Loa-
encephalopathy and the recommendations for its clinical
management;
(iv) the means of allaying the fears of the inhabitants that
they may suffer from Loa-encephalopathy; and
(v) the responsibilities of the Ministries of Health, APOC,
the national/APOC/NGDO Mectizan®  distribution teams
and of individual physicians and supporting hospital staff
in dealing with them.
The exact pathogenesis of Loa-encephalopathy is not pres-
ently understood, but the most probable primary factor
involved is the high concentration of Loa microfilariae in
the blood-stream. This problem could well be investigated
in experimentally-infected monkeys, especially Mandrillus
leucophaeus [7] and M. sphinx, both of which are good nat-
ural hosts of the nocturnally-periodic simian Loa and can
also readily be infected with the diurnally-periodic,Filaria Journal 2003, 2 http://filariajournal.com/content/2/S1/S1
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human L. loa. In the simian host, the spleen becomes
enlarged and granulomatous as it accomplishes its func-
tion of destroying a large proportion of the circulating Loa
microfilariae [8,9]. When the spleen is removed surgically,
very high concentrations of microfilariae will develop in
the peripheral blood (of the same order – up to 50,000/
ml – as those seen pre-treatment in human Loa-encepha-
lopathy patients), providing what is probably an excellent
model for studying drug-induced Loa-encephalopathy.
Furthermore, the diurnally-periodic human and the noc-
turnally-periodic simian parasites can be hybridised in the
simian host [10].
Although the main Chrysops vectors of the human and
simian parasites are different (day-biting at ground-level
and attracted by wood-smoke, for Chrysops silacea and C.
dimidiata, the main vectors of the human parasite; and
night-biting at forest canopy-level for C. langi and C. cen-
turionis, vectors of the simian parasite) [11], this raises the
possibility that under forest-dwelling conditions humans
may, over the course of time, become infected with simian
or hybrid strains of Loa having larger microfilariae and
possibly also different periodicities or other characteris-
tics. It is noteworthy that some of the patients with Loa-
encephalopathy following DEC treatment in the May-
umbe area of the DRC showed abnormal periodicities,
some of which were predominantly nocturnal. It is also
interesting that the Sanaga River, which flows through
Cameroon, is a well-known faunal barrier that separates
M. leucophaeus on the north-west bank from M. sphinx on
the south-east bank. It is thus possible that different
strains of human and simian Loa may exist and may have
spread to, or hybridised in, the human population in dif-
ferent areas.
Not only may studies of Loa in monkeys (recently re-initi-
ated in Cameroon by Drs. S. Wanji and P. Enyong) reveal
the possible influence of strains or sub-species of Loa on
the development of Loa-encephalopathy, but they should
facilitate investigations into the biochemical, haemato-
logical and histopathological changes that occur in this
condition, thus elucidating the mechanism, pathogenesis,
prevention and treatment of Loa-encephalopathy in
splenectomised monkeys with very high Loa mfs counts.
In the Report, careful consideration is also given by
Edwards et al., [12] and Mackenzie et al., [13] to the pos-
sible effects of a putative gene mutation in humans (anal-
ogous to that found in collie dogs and collie cross-breeds)
which renders its carriers fatally susceptible to the effects
of ivermectin. An absence or functional deficiency in P-
glycoprotein production (or its inhibition by alcohol or
some other food-stuff) in the apical membrane of the
brain capillary epithelial cells could result in dangerous
penetration of ivermectin into the brain. Informed current
opinion is that this putative alternative pathogenesis of
Loa-encephalopathy is less plausible than the mfs-
embolic hypothesis, but that the existence of any such
putative gene deficiency in humans could be determined
by experiment.
Another possible mechanism for Loa-encephalopathy is
the release of Wolbachia  organisms from dying adult
worms but, as these endosymbionts are seldom found in
Loa [14,15], this hypothesis is now considered somewhat
unlikely.
Finally, the report suggests that the prevention of Loa-
encephalopathy in humans could also be investigated
directly as, for example, by studying the potentialities of
using lower doses of ivermectin or by pre-treatment with
albendazole designed to lower the basic concentrations of
Loa microfilariae at a slower rate.
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